TY - JOUR
TI - Nanostructured Polymeric, Liposomal and Other Materials to Control the Drug Delivery for Cardiovascular Diseases
AU - Dimitrios Skourtis
AU - Dimitra Stavroulaki
AU - Varvara Athanasiou
AU - Panagiota G. Fragouli
AU - Hermis Iatrou
JO - Pharmaceutical Executive Europe
PY - 2020
VL - 12
TODO - 12
SP - 1160
PB - MDPI AG
SN - null
TODO - 10.3390/pharmaceutics12121160
TODO - 1,2 dioleoyl 3 trimethylammoniopropane;  4 [4 (1,3 benzodioxol 5 yl) 5 (2 pyridinyl) 1h imidazol 2 yl]benzamide;  4 [4 (4 fluorophenyl) 5 (2 methoxy 4 pyrimidinyl) 1 imidazolyl]cyclohexanol;  adrenomedullin;  adrenomedullin 2;  alpha interacting domain nanoparticle;  amo 1;  antisense oligonucleotide;  aspartylglutaminylarginylprolylaspartylarginylglutamylalanylprolylarginylserine;  atrial natriuretic factor;  az 7379;  calcium phosphate nanoparticle;  carbon nanoparticle;  cell penetrating peptide;  chitosan;  cholesterol;  curcumin;  cysteine arginine glutamic acid lysine alanine nanoparticle;  deoxyribozyme;  dioleoylphosphatidylcholine;  fibroblast growth factor 2;  gold nanoparticle;  graphene oxide;  hyaluronic acid;  hydrogenated soy phosphatidylcholine;  isoxazole;  laduviglusib;  liposome;  magnetic nanoparticle;  nanoparticle;  nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor;  PEGDA700 melamine;  phosphatidylcholine;  pitavastatin;  poly(3 amino 4 methoxybenzoic acid gelatin)nanoparticle;  poly(cyclohexane 1,4 diylacetone dimethylene ketal)nanoparticle;  poly(cystamine bisacrylamide diaminohexane)nanoparticle;  poly(ethylene glycol) poly(lactic acid)nanoparticle;  poly(gamma benzyl l glutamate) poly(ethylene glycol) poly(gamma benzyl l glutamate)nanoparticle;  poly(glycidyl methacrylate)nanoparticle;  poly(n isopropylacrylamide co propylacrylic acid co butyl acrylate)nanoparticle;  poly(norbornene)nanoparticle;  polyethylene glycol distearoylphosphatidylethanolamine;  polyethylene glycol hydrogenated soy phosphatidylcholine;  polyglactin nanoparticle;  polymer nanoparticle;  puerarin;  reduced nicotinamide adenine dinucleotide phosphate oxidase 2;  resveratrol;  scatter factor;  silica nanoparticle;  somatomedin C;  timbetasin;  trisubsituted 3,4,5 isoxazole;  ubidecarenone;  unclassified drug;  vasculotropin, acute heart infarction;  adipose tissue cell;  adipose tissue derived stromal cell;  angiogenesis;  antiangiogenic activity;  apoptosis;  Article;  cardiac muscle cell;  cardiovascular disease;  coronary artery disease;  diabetic cardiomyopathy;  drug delivery system;  enzyme linked immunosorbent assay;  flow cytometry;  heart arrhythmia;  heart failure;  heart function;  heart infarction;  heart infarction size;  heart muscle blood flow;  heart protection;  human;  myocardial ischemia reperfusion injury;  nanomedicine;  nonhuman;  oxidative stress;  particle size;  peripheral occlusive artery disease;  real time polymerase chain reaction;  stroma cell;  zeta potential
TODO - Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year, representing one third of global mortality. As existing therapies still have limited success, due to the inability to control the biodistribution of the currently approved drugs, the quality of life of these patients is modest. The advent of nanomedicine has brought new insights in innovative treatment strategies. For this reason, several novel nanotechnologies have been developed for both targeted and prolonged delivery of therapeutics to the cardiovascular system to minimize side effects. In this regard, nanoparticles made of natural and/or synthetic nanomaterials, like liposomes, polymers or inorganic materials, are emerging alternatives for the encapsulation of already approved drugs to control their delivery in a targeted way. Therefore, nanomedicine has attracted the attention of the scientific community as a potential platform to deliver therapeutics to the injured heart. In this review, we discuss the current types of biomaterials that have been investigated as potential therapeutic interventions for CVDs as they open up a host of possibilities for more targeted and effective therapies, as well as minimally invasive treatments. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
ER -